Your browser doesn't support javascript.
loading
Identification of Reduced ERAP2 Expression and a Novel HLA Allele as Components of a Risk Score for Susceptibility to Liver Injury Due to Amoxicillin-Clavulanate.
Nicoletti, Paola; Dellinger, Andrew; Li, Yi Ju; Barnhart, Huiman X; Chalasani, Naga; Fontana, Robert J; Odin, Joseph A; Serrano, Jose; Stolz, Andrew; Etheridge, Amy S; Innocenti, Federico; Govaere, Olivier; Grove, Jane I; Stephens, Camilla; Aithal, Guruprasad P; Andrade, Raul J; Bjornsson, Einar S; Daly, Ann K; Lucena, M Isabel; Watkins, Paul B.
Afiliação
  • Nicoletti P; Department of Genetics and Genomic Science, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: paola.nicoletti@mssm.edu.
  • Dellinger A; Duke Molecular Physiology Institute, Duke University, Durham, North Carolina.
  • Li YJ; Duke Molecular Physiology Institute, Duke University, Durham, North Carolina; Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina.
  • Barnhart HX; Duke Molecular Physiology Institute, Duke University, Durham, North Carolina; Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina.
  • Chalasani N; Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana.
  • Fontana RJ; University of Michigan, Ann Arbor, Michigan.
  • Odin JA; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Serrano J; National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.
  • Stolz A; University of Southern California, Los Angeles, California.
  • Etheridge AS; University of North Carolina Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Innocenti F; University of North Carolina Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Govaere O; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Grove JI; Nottingham Digestive Diseases Centre and National Institute for Health Research Nottingham Biomedical Research Centre at the Nottingham University Hospital National Health Service Trust, Nottingham, United Kingdom; University of Nottingham, Nottingham, United Kingdom.
  • Stephens C; Servicios de Digestivo y Farmacologia Clínica, Instituto de Investigación Biomédica de Málaga (IBIMA_Plataforma Bionand), Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Ma
  • Aithal GP; Nottingham Digestive Diseases Centre and National Institute for Health Research Nottingham Biomedical Research Centre at the Nottingham University Hospital National Health Service Trust, Nottingham, United Kingdom; University of Nottingham, Nottingham, United Kingdom.
  • Andrade RJ; Servicios de Digestivo y Farmacologia Clínica, Instituto de Investigación Biomédica de Málaga (IBIMA_Plataforma Bionand), Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Ma
  • Bjornsson ES; Department of Internal Medicine, Landspitali University Hospital, Reykjavik, Iceland; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Daly AK; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Lucena MI; Servicios de Digestivo y Farmacologia Clínica, Instituto de Investigación Biomédica de Málaga (IBIMA_Plataforma Bionand), Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Ma
  • Watkins PB; University of North Carolina Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; University of North Carolina Institute for Drug Safety Sciences, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Gastroenterology ; 164(3): 454-466, 2023 03.
Article em En | MEDLINE | ID: mdl-36496055
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença Hepática Induzida por Substâncias e Drogas / Antibacterianos Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Gastroenterology Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença Hepática Induzida por Substâncias e Drogas / Antibacterianos Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Gastroenterology Ano de publicação: 2023 Tipo de documento: Article